Owing to that the previous study of the investigators showed that SBRT plus pembrolizumab and
trametinib provided favorable outcomes compared with SBRT plus gemcitabine for pancreatic
cancer, therefore, the investigators aim to further investigate the efficacy and safety of
SBRT plus another kind of immunotherapy, namely adoptive cell therapy (vNKT cell), for
advanced pancreatic cancer.